CAPA In-vitro Oocyte Maturation
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- Number of mature oocytes
Study Overview
Brief Summary
In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 50 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Patients aged from 18-50 years old
- •Patients seek fertility preservation services
- •Patients seek oocyte retrieval services
Exclusion Criteria
- •Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)
Outcomes
Primary Outcomes
Number of mature oocytes
Time Frame: 1 week
Number of mature oocytes after IVM
Secondary Outcomes
No secondary outcomes reported
Investigators
Chung Pui Wah Jacqueline
Associate Professor
Chinese University of Hong Kong